Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07050186 · ClinicalTrials.gov registry record · Phase 2
Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma
A Phase 2 study of Metastatic NUT Carcinoma and Unresectable NUT Carcinoma, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT07050186 is a Phase 2 study of Metastatic NUT Carcinoma and Unresectable NUT Carcinoma that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07050186, a Phase 2 study of Metastatic NUT Carcinoma and Unresectable NUT Carcinoma, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well cemiplimab works in treating patients with nuclear protein of testis (NUT) carcinoma for which no treatment is currently available (incurable) and that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Biopsy Procedure
- BIOLOGICAL Cemiplimab
- OTHER Digital Photography
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-08-15 |
| Est. Completion | 2035-11-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07050186
The ClinicalTrials.gov registry entry for NCT07050186 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic NUT Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07050186 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT07050186 about?
NCT07050186 is a clinical study titled "Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma". This phase II trial studies how well cemiplimab works in treating patients with nuclear protein of testis (NUT) carcinoma for which no treatment is currently available (incurable) and that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be rem...
What is the current status of trial NCT07050186?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2025-08-15. Estimated completion is 2035-11-20.
What conditions does trial NCT07050186 study?
This clinical trial studies the following conditions: Metastatic NUT Carcinoma, Unresectable NUT Carcinoma.
What interventions are being tested in trial NCT07050186?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy Procedure (PROCEDURE), Cemiplimab (BIOLOGICAL), Digital Photography (OTHER).
Who is sponsoring clinical trial NCT07050186?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07050186 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic NUT Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma
RECRUITING · Phase 1
-
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.